Singapore scientists have unveiled an AI tool that predicts liver cancer relapse with 82% accuracy, turning pathology slides ...

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma ...

Singaporean researchers have developed an artificial intelligence-powered scoring system capable of predicting the recurrence of hepatocellular carcinoma, the most common type of liver cancer, with ...

Developed by scientists from the Institute of Molecular and Cell Biology (IMCB) under the agency in collaboration with the ...

A higher NLR and rapid NLR shift between weeks 2 and 4 was strongly associated with RILD risk in patients with HCC.

SAN FRANCISCO, CA, USA I July 21, 2025 I AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology ...

Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

AI tool predicts liver cancer relapse with 82% accuracy, tackling a disease causing third-highest cancer-related deaths ...

Cambridge-based biotech spinout Spliceor has secured investment from the Cell and Gene Therapy Catapult (CGT Catapult) to ...

Summit Therapeutics' leading candidate is showing promise in a key oncology market. Three years ago, Summit Therapeutics ...

中央医院解剖病理学部兼新科研分子与细胞生物学研究院首席科学家杨宝诚博士说，本地有高达70%的肝癌患者五年内病症会复发。“TIMES在预测这些结果方面取得了重大进展，使临床医生能够尽可能提前介入。这将显著提升患者护理质量和存活率。” ...